Literature DB >> 26530519

Angiogenesis and Vascular Endothelial Growth Factor-A Expression Associated with Inflammation in Pediatric Crohn's Disease.

J Leslie Knod1, Kelly Crawford1, Mary Dusing1, Margaret H Collins2, Artur Chernoguz1, Jason S Frischer3,4.   

Abstract

BACKGROUND AND AIMS: Angiogenesis is a component of chronic inflammatory diseases including inflammatory bowel disease. Some studies describe increased angiogenesis associated with acute disease in adult Crohn's disease and ulcerative colitis, while animal models aid investigations of mechanism and pathophysiology of angiogenesis. We aim to explore the role of angiogenesis and its pathways in pediatric Crohn's disease.
METHODS: Surgical specimens were obtained from pediatric Crohn's disease (both inflamed and non-inflamed regions of ileum) and control patients. Samples were examined for inflammation, microvessel density, and molecular expression of vascular endothelial growth factor-A, platelet-derived growth factor-β, angiopoietin-1, and angiopoietin-2.
RESULTS: Angiogenesis and inflammation were increased in parallel in Crohn's disease compared to controls. We also discovered increased angiogenesis in Crohn's disease tissue that was relatively free of inflammatory disease. Vascular endothelial growth factor-A gene expression (P = 0.034) was elevated in Crohn's disease over controls, while gene expression of platelet-derived growth factor-β (P = 0.069), angiopoietin-1 (P = 0.206), and angiopoietin-2 (P = 0.082) was not significantly elevated.
CONCLUSIONS: We confirm that inflammation-associated angiogenesis is upregulated in pediatric Crohn's disease. This population also exhibits elevated mucosal angiogenesis at the surgical margin with limited inflammation. This suggests that angiogenesis is an additional pathologic characteristic to potentially identify normal mucosa and margins of surgical resection that are uninvolved with disease and, furthermore, may have implications for monitoring complete disease remission. We further identify the vascular endothelial growth factor-A pathway involvement in the disease process, which may serve as a future molecular target for anti-angiogenic therapy in inflammatory bowel disease.

Entities:  

Keywords:  Angiogenesis; Crohn’s disease; Pediatric; VEGF-A

Mesh:

Substances:

Year:  2015        PMID: 26530519     DOI: 10.1007/s11605-015-3002-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  49 in total

1.  Long-term remission of Crohn's disease treated with thalidomide: a seminal case report.

Authors:  S J Fishman; N R Feins; R J D' Amato; J Folkman
Journal:  Angiogenesis       Date:  1999       Impact factor: 9.596

2.  Angiogenesis blockade as a new therapeutic approach to experimental colitis.

Authors:  Silvio Danese; Miquel Sans; David M Spencer; Ivy Beck; Fernando Doñate; Marian L Plunkett; Carol de la Motte; Raymond Redline; David E Shaw; Alan D Levine; Andrew P Mazar; Claudio Fiocchi
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

Review 3.  Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades.

Authors:  Livija Deban; Carmen Correale; Stefania Vetrano; Alberto Malesci; Silvio Danese
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

4.  Crohn's disease: influence of age at diagnosis on site and clinical type of disease.

Authors:  J M Polito; B Childs; E D Mellits; A Z Tokayer; M L Harris; T M Bayless
Journal:  Gastroenterology       Date:  1996-09       Impact factor: 22.682

5.  Distinct phenotype of early childhood inflammatory bowel disease.

Authors:  Thankam Paul; Audrey Birnbaum; Deb K Pal; Nanci Pittman; Clare Ceballos; Neal S LeLeiko; Keith Benkov
Journal:  J Clin Gastroenterol       Date:  2006-08       Impact factor: 3.062

6.  Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease.

Authors:  Sergio Rutella; Gionata Fiorino; Stefania Vetrano; Carmen Correale; Antonino Spinelli; Nico Pagano; Vincenzo Arena; Nicola Maggiano; Alessandro Repici; Alberto Malesci; Silvio Danese
Journal:  Am J Gastroenterol       Date:  2011-03-01       Impact factor: 10.864

7.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 9.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

10.  Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF.

Authors:  Ganna Tolstanova; Tetyana Khomenko; Xiaoming Deng; Longchuan Chen; Andrzej Tarnawski; Amrita Ahluwalia; Sandor Szabo; Zsuzsanna Sandor
Journal:  J Pharmacol Exp Ther       Date:  2008-12-05       Impact factor: 4.030

View more
  6 in total

1.  FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities.

Authors:  Rana Rais; Weiwei Jiang; Huihong Zhai; Krystyna M Wozniak; Marigo Stathis; Kristen R Hollinger; Ajit G Thomas; Camilo Rojas; James J Vornov; Michael Marohn; Xuhang Li; Barbara S Slusher
Journal:  JCI Insight       Date:  2016-08-04

2.  Mechanism of Peitu Shengjin Formula Shenlingbaizhu Powder in Treating Bronchial Asthma and Allergic Colitis through Different Diseases with Simultaneous Treatment Based on Network Pharmacology and Molecular Docking.

Authors:  Liying Zeng; Shaodan Sun; Peiwen Chen; Qina Ye; Xiaoling Lin; Hongjun Wan; Yawen Cai; Xiaogang Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-09       Impact factor: 2.650

3.  Thalidomide Inhibits Angiogenesis via Downregulation of VEGF and Angiopoietin-2 in Crohn's Disease.

Authors:  Lin Wang; Shengnan Wang; Aijuan Xue; Jieru Shi; Cuifang Zheng; Ying Huang
Journal:  Inflammation       Date:  2020-11-18       Impact factor: 4.092

4.  Hypoxia induced mitogenic factor (HIMF) triggers angiogenesis by increasing interleukin-18 production in myoblasts.

Authors:  Chen-Ming Su; I-Ching Wang; Shan-Chi Liu; Yi Sun; Lulu Jin; Shih-Wei Wang; Hsiang-Ping Lee; Wen-Pei Tseng; Chih-Hsin Tang
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

5.  Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging in the activity staging of terminal ileum Crohn's disease.

Authors:  Yin-Chen Wu; Ze-Bin Xiao; Xue-Hua Lin; Xian-Ying Zheng; Dai-Rong Cao; Zhong-Shuai Zhang
Journal:  World J Gastroenterol       Date:  2020-10-21       Impact factor: 5.742

Review 6.  Role of mesenteric component in Crohn's disease: A friend or foe?

Authors:  Yi Yin; Zhen-Xing Zhu; Zhun Li; Yu-Sheng Chen; Wei-Ming Zhu
Journal:  World J Gastrointest Surg       Date:  2021-12-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.